T
Todd M. Pitts
Researcher at Anschutz Medical Campus
Publications - 105
Citations - 3733
Todd M. Pitts is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 28, co-authored 94 publications receiving 3174 citations. Previous affiliations of Todd M. Pitts include University of Colorado Denver & University of Colorado Boulder.
Papers
More filters
Journal ArticleDOI
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler,Aik Choon Tan,Colin D. Weekes,Antonio Jimeno,Stephen Leong,Todd M. Pitts,John J. Arcaroli,Wells A. Messersmith,S. Gail Eckhardt +8 more
TL;DR: This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.
Journal ArticleDOI
Activation of gene expression in human neutrophils by high mobility group box 1 protein
Jong Sung Park,John J. Arcaroli,Ho Kee Yum,Huan Yang,Haichao Wang,Kuang Yao Yang,Kang Hyeon Choe,Derek Strassheim,Todd M. Pitts,Kevin J. Tracey,Edward Abraham +10 more
TL;DR: It is demonstrated that HMGB1 increases the nuclear translocation of NF-kappaB and enhances the expression of proinflammatory cytokines in human neutrophils and is an effective stimulus of neutrophil activation that can contribute to development of a proinflammatory phenotype in diseases characterized by excessively high levels ofHMGB1.
Journal ArticleDOI
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
Anna Capasso,Julie E. Lang,Todd M. Pitts,Kimberly R. Jordan,Christopher H. Lieu,Sarah Lindsey Davis,Jennifer R. Diamond,Scott Kopetz,J. Barbee,Jacob N. Peterson,Brian M. Freed,Betelehem W. Yacob,Stacey M. Bagby,Wells A. Messersmith,Jill E. Slansky,Roberta Pelanda,S.G. Eckhardt +16 more
TL;DR: Hu-CB-BRGS mice represent an in vivo model to study immune checkpoint blockade to human tumors and provide a relevant preclinical animal model to facilitate prioritization of hypothesis-driven combination immunotherapies.
Journal ArticleDOI
Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Judy Mouchawar,Christopher Korch,Tim Byers,Todd M. Pitts,Efang Li,Margaret R. E. McCredie,Graham G. Giles,John L. Hopper,Melissa C. Southey +8 more
TL;DR: Germline TP53 mutations play a larger role in early-onset breast cancer than previously thought, and in this context, can be evident outside clinically defined Li-Fraumeni families.
Journal ArticleDOI
Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Todd M. Pitts,Aik Choon Tan,Gillian N. Kulikowski,John J. Tentler,Amy M. Brown,Sara A. Flanigan,Stephen Leong,Christopher D. Coldren,Fred R. Hirsch,Marileila Varella-Garcia,Christopher Korch,S. Gail Eckhardt +11 more
TL;DR: Predictive biomarkers for an IGFIR tyrosine kinase inhibitor, OSI-906, are developed and characterize that could be applied in CRC-specific studies of this agent and indicate that an integrated approach to the development of individualized therapy is feasible and should be applied early in theDevelopment of novel agents.